47 related articles for article (PubMed ID: 19318229)
1. Growth inhibition by tyrosine kinase inhibitors in mesothelioma cell lines.
Nutt JE; O'Toole K; Gonzalez D; Lunec J
Eur J Cancer; 2009 Jun; 45(9):1684-91. PubMed ID: 19318229
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of epidermal growth factor receptor signaling in malignant pleural mesothelioma.
Jänne PA; Taffaro ML; Salgia R; Johnson BE
Cancer Res; 2002 Sep; 62(18):5242-7. PubMed ID: 12234991
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of proliferation, migration, and matrix metalloprotease production in malignant mesothelioma cells by tyrosine kinase inhibitors.
Liu Z; Klominek J
Neoplasia; 2004; 6(6):705-12. PubMed ID: 15720796
[TBL] [Abstract][Full Text] [Related]
4. The selective epidermal growth factor receptor tyrosine kinase inhibitor PD153035 suppresses expression of prometastasis phenotypes in malignant pleural mesothelioma cells in vitro.
Cole GW; Alleva AM; Reddy RM; Maxhimer JB; Zuo J; Schrump DS; Nguyen DM
J Thorac Cardiovasc Surg; 2005 May; 129(5):1010-7. PubMed ID: 15867774
[TBL] [Abstract][Full Text] [Related]
5. Enhancement of chemosensitivity and programmed cell death by tyrosine kinase inhibitors correlates with EGFR expression in non-small cell lung cancer cells.
Lei W; Mayotte JE; Levitt ML
Anticancer Res; 1999; 19(1A):221-8. PubMed ID: 10226546
[TBL] [Abstract][Full Text] [Related]
6. AEE788: a dual family epidermal growth factor receptor/ErbB2 and vascular endothelial growth factor receptor tyrosine kinase inhibitor with antitumor and antiangiogenic activity.
Traxler P; Allegrini PR; Brandt R; Brueggen J; Cozens R; Fabbro D; Grosios K; Lane HA; McSheehy P; Mestan J; Meyer T; Tang C; Wartmann M; Wood J; Caravatti G
Cancer Res; 2004 Jul; 64(14):4931-41. PubMed ID: 15256466
[TBL] [Abstract][Full Text] [Related]
7. Alterations in EGF-dependent proliferative and phosphorylation events in squamous cell carcinoma cell lines by a tyrosine kinase inhibitor.
Brunton VG; Carlin S; Workman P
Anticancer Drug Des; 1994 Aug; 9(4):311-29. PubMed ID: 7916899
[TBL] [Abstract][Full Text] [Related]
8. Vascular endothelial growth factor is an autocrine growth factor in human malignant mesothelioma.
Strizzi L; Catalano A; Vianale G; Orecchia S; Casalini A; Tassi G; Puntoni R; Mutti L; Procopio A
J Pathol; 2001 Apr; 193(4):468-75. PubMed ID: 11276005
[TBL] [Abstract][Full Text] [Related]
9. The growth inhibitory effect of lapatinib, a dual inhibitor of EGFR and HER2 tyrosine kinase, in gastric cancer cell lines.
Kim JW; Kim HP; Im SA; Kang S; Hur HS; Yoon YK; Oh DY; Kim JH; Lee DS; Kim TY; Bang YJ
Cancer Lett; 2008 Dec; 272(2):296-306. PubMed ID: 18774637
[TBL] [Abstract][Full Text] [Related]
10. PTK787/ZK 222584, a novel and potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, impairs vascular endothelial growth factor-induced responses and tumor growth after oral administration.
Wood JM; Bold G; Buchdunger E; Cozens R; Ferrari S; Frei J; Hofmann F; Mestan J; Mett H; O'Reilly T; Persohn E; Rösel J; Schnell C; Stover D; Theuer A; Towbin H; Wenger F; Woods-Cook K; Menrad A; Siemeister G; Schirner M; Thierauch KH; Schneider MR; Drevs J; Martiny-Baron G; Totzke F
Cancer Res; 2000 Apr; 60(8):2178-89. PubMed ID: 10786682
[TBL] [Abstract][Full Text] [Related]
11. t(8;21) acute myeloid leukaemia cells are dependent on vascular endothelial growth factor (VEGF)/VEGF receptor type2 pathway and phosphorylation of Akt.
Imai N; Shikami M; Miwa H; Suganuma K; Hiramatsu A; Watarai M; Satoh A; Itoh M; Imamura A; Mihara H; Nitta M
Br J Haematol; 2006 Dec; 135(5):673-82. PubMed ID: 17107349
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of breast cancer cell growth in vitro by a tyrosine kinase inhibitor.
Reddy KB; Mangold GL; Tandon AK; Yoneda T; Mundy GR; Zilberstein A; Osborne CK
Cancer Res; 1992 Jul; 52(13):3636-41. PubMed ID: 1617636
[TBL] [Abstract][Full Text] [Related]
13. Discovery of 4-benzylamino-substituted α-carbolines as a novel class of receptor tyrosine kinase inhibitors.
Krug M; Wichapong K; Erlenkamp G; Sippl W; Schächtele C; Totzke F; Hilgeroth A
ChemMedChem; 2011 Jan; 6(1):63-72. PubMed ID: 21140395
[TBL] [Abstract][Full Text] [Related]
14. Diarachidonoylphosphoethanolamine induces necrosis/necroptosis of malignant pleural mesothelioma cells.
Kaku Y; Tsuchiya A; Kanno T; Nakano T; Nishizaki T
Cell Signal; 2015 Sep; 27(9):1713-9. PubMed ID: 26004138
[TBL] [Abstract][Full Text] [Related]
15. Biochemical characterization of a novel type-II VEGFR2 kinase inhibitor: comparison of binding to non-phosphorylated and phosphorylated VEGFR2.
Iwata H; Imamura S; Hori A; Hixon MS; Kimura H; Miki H
Bioorg Med Chem; 2011 Sep; 19(18):5342-51. PubMed ID: 21885287
[TBL] [Abstract][Full Text] [Related]
16. Ligand-Based Pharmacophore Modeling, Molecular Docking, and Molecular Dynamic Studies of Dual Tyrosine Kinase Inhibitor of EGFR and VEGFR2.
Sangande F; Julianti E; Tjahjono DH
Int J Mol Sci; 2020 Oct; 21(20):. PubMed ID: 33096664
[TBL] [Abstract][Full Text] [Related]
17. Vascular endothelial growth factor receptor 2 as a marker for malignant vascular tumors and mesothelioma: an immunohistochemical study of 262 vascular endothelial and 1640 nonvascular tumors.
Miettinen M; Rikala MS; Rys J; Lasota J; Wang ZF
Am J Surg Pathol; 2012 Apr; 36(4):629-39. PubMed ID: 22314185
[TBL] [Abstract][Full Text] [Related]
18. Immunohistochemical determination of EGFR-tyrosine kinase inhibition in clinical samples.
Malik SN; Bedolla RG; Hidalgo M; Brattain MG; Kreisberg JI
Methods Mol Med; 2003; 85():135-40. PubMed ID: 12710204
[No Abstract] [Full Text] [Related]
19. Headspace analysis of mesothelioma cell lines differentiates biphasic and epithelioid sub-types.
Little LD; Carolan VA; Allen KE; Cole LM; Haywood-Small SL
J Breath Res; 2020 Sep; 14(4):046011. PubMed ID: 32731209
[TBL] [Abstract][Full Text] [Related]
20. Update on the molecular biology of malignant mesothelioma.
Lee AY; Raz DJ; He B; Jablons DM
Cancer; 2007 Apr; 109(8):1454-61. PubMed ID: 17348013
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
